Announced
Completed
Synopsis
Clarus Therapeutics, a pharmaceutical company, went public via a SPAC merger with Blue Water Acquisition, a special purposes acquisition company, in a $379m deal. “At Clarus, our goal is to develop and commercialize androgen and metabolic therapies for unmet medical conditions in men and women. My sincere thanks to our investors, employees, board of directors, and advisors for supporting our vision and making this transaction a success," Robert Dudley, Clarus President and CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.